We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+22.48%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$143M
AUM Growth
+$1.74M
Cap. Flow
-$14.9M
Cap. Flow %
-10.35%
Top 10 Hldgs %
73.75%
Holding
32
New
5
Increased
9
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$6.45M
2
WHWK
Whitehawk Therapeutics
WHWK
+$5.31M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$4.95M
4
AVLN
Avalyn Pharma
AVLN
+$3.32M
5
ARTV
Artiva Biotherapeutics
ARTV
+$2.37M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$26.1M
2
OCS icon
Oculis Holding
OCS
+$2.61M
3
RVMD icon
Revolution Medicines
RVMD
+$2.54M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$1.61M
5
DRUG
Bright Minds Biosciences
DRUG
+$1.51M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Acuta Capital Partners held 32 positions worth $143M, up 1.2% from $142M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Acuta Capital Partners withdrew a net $14.9M in Q2 2026, closing 9 positions and reducing 6 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $26.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in ArriVent BioPharma worth $7.6M.

  • Acuta Capital Partners's largest Q2 2026 buy was ArriVent BioPharma: 218,694 shares worth $7.6M.
  • Acuta Capital Partners added most to Whitehawk Therapeutics in Q2 2026, an estimated $5.31M increase.
  • Acuta Capital Partners's biggest Q2 2026 reduction was Bright Minds Biosciences, cutting an estimated $1.51M.
  • Acuta Capital Partners fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $26.1M.
  • Acuta Capital Partners's ten largest holdings make up 74% of its $143M portfolio in Q2 2026.
  • Acuta Capital Partners opened 5 new positions and closed 9 in Q2 2026.
  • Acuta Capital Partners's portfolio value rose 1.2% quarter-over-quarter to $143M.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.